Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Lancet
    April 2024
  1. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
    Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
    Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
    >> Share

  2. DAUBENBERGER CA, Silva JC
    First-generation malaria vaccine successfully implemented in three African countries.
    Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
    >> Share

    March 2024
  3. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  4. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  5. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  6. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    >> Share

  7. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  8. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    >> Share

    February 2024
  9. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    >> Share

  10. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    >> Share

  11. ABRAVANEL F, Lhomme S
    Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen.
    Lancet. 2024 Feb 19:S0140-6736(23)02455-8. doi: 10.1016/S0140-6736(23)02455.
    >> Share

  12. HUANG S, Zhang X, Su Y, Zhuang C, et al
    Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2024 Feb 19:S0140-6736(23)02234-1. doi: 10.1016/S0140-6736(23)02234.
    >> Share

  13. CARPIANO RM, Callahan T, Elharake JA, Hotez P, et al
    Vaccination and the defence of democracy - Authors' reply.
    Lancet. 2024;403:529-530.
    >> Share

  14. ALBIN RL
    Vaccination and the defence of democracy.
    Lancet. 2024;403:529.
    >> Share

  15. DOPPEN M, Kearns C, Hills T, Weatherall M, et al
    Intramuscular vaccination needle length: a call to arms.
    Lancet. 2024;403:528-529.
    >> Share

  16. NNAJI CA, Amaechi UA, Wiysonge CS
    R21/Matrix-M vaccine: optimising supply, maximising impact.
    Lancet. 2024;403:525.
    >> Share

  17. THE LANCET
    Malaria vaccines: a test for global health.
    Lancet. 2024;403:503.
    >> Share

  18. ADEPOJU P
    Routine malaria vaccinations begin.
    Lancet. 2024;403:423.
    >> Share

  19. MOORTHY V, Hamel MJ, Smith PG
    Malaria vaccines for children: and now there are two.
    Lancet. 2024 Feb 1:S0140-6736(23)02743-5. doi: 10.1016/S0140-6736(23)02743.
    >> Share

  20. DATOO MS, Dicko A, Tinto H, Ouedraogo JB, et al
    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
    Lancet. 2024 Feb 1:S0140-6736(23)02511-4. doi: 10.1016/S0140-6736(23)02511.
    >> Share

    January 2024
  21. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    >> Share

  22. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.
    >> Share

  23. TERAI M, Sato T
    Individualised neoantigen cancer vaccine therapy.
    Lancet. 2024 Jan 18:S0140-6736(23)02463-7. doi: 10.1016/S0140-6736(23)02463.
    >> Share

  24. ALVES L
    Brazil to start widespread dengue vaccinations.
    Lancet. 2024;403:133.
    >> Share

  25. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.
    >> Share


  26. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    >> Share

    December 2023
  27. THUMBI SM, Blumberg L, le Roux K, Salahuddin N, et al
    A call to accelerate an end to human rabies deaths.
    Lancet. 2023;400:2261-2264.
    >> Share

  28. KARIM SSA, Sikazwe I
    Building on Pasteur's legacy: producing vaccines in Africa.
    Lancet. 2023;400:2164-2166.
    >> Share

    November 2023
  29. KANG G
    Success from the South: the rotavirus vaccine story and its lessons.
    Lancet. 2023 Nov 28:S0140-6736(23)02520-5. doi: 10.1016/S0140-6736(23)02520.
    >> Share

  30. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    >> Share

  31. DU Z, Wang L, Bai Y, Pei Y, et al
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    >> Share

    October 2023
  32. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.
    >> Share

  33. ADEPOJU P
    Malaria community welcomes WHO vaccine approval.
    Lancet. 2023;402:1316.
    >> Share

    September 2023
  34. YANG C, Lapp L, Tebbutt SJ
    Overcoming COVID-19 vaccine hesitancy hurdles.
    Lancet. 2023;402:1129-1130.
    >> Share

  35. AARS OK, Schwalbe N
    Bold moves for vaccine manufacturing equity.
    Lancet. 2023;402:771-772.
    >> Share

    August 2023
  36. DAI L, Duan H, Liu X, Zhou H, et al
    Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
    Lancet. 2023;402:687-689.
    >> Share

  37. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    >> Share

    July 2023
  38. AGUS DB, Nguyen A, Bell J
    Successful adult vaccine drives must centre disability inclusion - Authors' reply.
    Lancet. 2023;402:370.
    >> Share

  39. ROTENBERG S, Downer M
    Successful adult vaccine drives must centre disability inclusion.
    Lancet. 2023;402:369-370.
    >> Share

  40. ZHOU J, Zhang Y, Mo K, Newbert H, et al
    mRNA vaccines do not stop with COVID-19.
    Lancet. 2023 Jul 27:S0140-6736(23)01514-3. doi: 10.1016/S0140-6736(23)01514.
    >> Share

  41. SAIED AA
    Building Africa's first mRNA vaccine facility.
    Lancet. 2023;402:287-288.
    >> Share

  42. DEVI S
    12 countries to get first doses of malaria vaccine.
    Lancet. 2023;402:172.
    >> Share

    June 2023
  43. SCHNEIDER M, Narciso-Abraham M, Hadl S, McMahon R, et al
    Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 12:S0140-6736(23)00641-4. doi: 10.1016/S0140-6736(23)00641.
    >> Share

  44. STEPHENSON KE
    Live-attenuated Chikungunya vaccine: a possible new era.
    Lancet. 2023 Jun 12:S0140-6736(23)01170-4. doi: 10.1016/S0140-6736(23)01170.
    >> Share

    May 2023
  45. MFINANGA SG, Gatei W, Tinuga F, Mwengee WMP, et al
    Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution.
    Lancet. 2023;401:1649.
    >> Share

  46. ZAROCOSTAS J
    Gavi unveils malaria vaccine plans.
    Lancet. 2023;401:1485.
    >> Share

    April 2023
  47. ALOMARI O
    Why vaccinations should be a top priority in earthquake relief efforts.
    Lancet. 2023;401:1263-1264.
    >> Share

    March 2023
  48. OKOKHERE PO
    Finding a safe and effective vaccine for the Lassa virus.
    Lancet. 2023 Mar 16:S0140-6736(23)00093-4. doi: 10.1016/S0140-6736(23)00093.
    >> Share

  49. TSCHISMAROV R, Van Damme P, Germain C, De Coster I, et al
    Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
    Lancet. 2023 Mar 16:S0140-6736(23)00048-X. doi: 10.1016/S0140-6736(23)00048.
    >> Share

  50. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    >> Share

  51. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.
    >> Share

  52. STOCKWELL M
    Effect of a nationwide intervention of electronic letters with behavioural nudges on influenza vaccination in older adults in Denmark.
    Lancet. 2023 Mar 3:S0140-6736(23)00453-1. doi: 10.1016/S0140-6736(23)00453.
    >> Share

  53. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00349-5. doi: 10.1016/S0140-6736(23)00349.
    >> Share

  54. CARPIANO RM, Callaghan T, DiResta R, Brewer NT, et al
    Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era.
    Lancet. 2023 Mar 2:S0140-6736(23)00136-8. doi: 10.1016/S0140-6736(23)00136.
    >> Share

    January 2023
  55. HAMER MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, et al
    Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
    Lancet. 2023;401:294-302.
    >> Share

  56. MANNO D
    Developing a vaccine against Marburg virus disease.
    Lancet. 2023;401:251-253.
    >> Share

  57. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    >> Share

  58. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    >> Share

    December 2022
  59. BUTLER CC, Hobbs FDR, Gbinigie OA, Rahman NM, et al
    Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Lancet. 2022 Dec 22:S0140-6736(22)02597-1. doi: 10.1016/S0140-6736(22)02597.
    >> Share

  60. ZAMAN K, Bandyopadhyay AS, Hoque M, Gast C, et al
    Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
    Lancet. 2022 Dec 7:S0140-6736(22)02397-2. doi: 10.1016/S0140-6736(22)02397.
    >> Share

  61. NANQUE LM, Fisker AB
    Maximising the lessons learned from trial data after emergency use listing of a novel oral polio vaccine.
    Lancet. 2022 Dec 7:S0140-6736(22)02455-2. doi: 10.1016/S0140-6736(22)02455.
    >> Share

    November 2022
  62. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    >> Share

  63. ISBA R, Brennan L, Davies N, Knight J, et al
    Measles, mumps, and rubella vaccination coverage in children younger than 5 years attending a paediatric emergency department in Manchester, UK: a cross-sectional observational study.
    Lancet. 2022;400 Suppl 1:S51.
    >> Share

  64. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    >> Share

  65. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    >> Share

    October 2022
  66. KLAPSA D, Wilton T, Zealand A, Bujaki E, et al
    Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.
    Lancet. 2022;400:1531-1538.
    >> Share

  67. HILL M, Pollard AJ
    Detection of poliovirus in London highlights the value of sewage surveillance.
    Lancet. 2022;400:1491-1492.
    >> Share

  68. AGUS DB, Nguyen A, Sall AA, Bell J, et al
    COVID-19 and other adult vaccines can drive global disease prevention.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02084.
    >> Share

  69. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
    The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
    Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.
    >> Share

  70. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    >> Share

  71. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.
    >> Share

    September 2022
  72. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.
    >> Share

  73. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.
    >> Share

    August 2022
  74. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Influenza.
    Lancet. 2022;400:693-706.
    >> Share

  75. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.
    >> Share

    July 2022
  76. DURRHEIM DN
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.
    >> Share

  77. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.
    >> Share

    June 2022
  78. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    >> Share

  79. LADHANI SN
    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.
    >> Share

  80. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    >> Share

  81. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    >> Share

  82. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    >> Share

  83. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    >> Share

    May 2022
  84. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    >> Share

  85. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    >> Share

  86. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    >> Share

  87. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    >> Share

  88. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.
    >> Share

    April 2022
  89. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    >> Share

  90. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.
    >> Share

  91. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    >> Share

  92. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.
    >> Share

  93. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.
    >> Share

  94. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    >> Share

  95. WINTER AK, Moss WJ
    Rubella.
    Lancet. 2022;399:1336-1346.
    >> Share

  96. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    >> Share

  97. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.
    >> Share

    March 2022
  98. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.
    >> Share

  99. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.
    >> Share

  100. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    >> Share

  101. USHER AD
    CEPI launches 100-day vaccine "moonshot".
    Lancet. 2022;399:1107-1108.
    >> Share

  102. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    >> Share

  103. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.
    >> Share

  104. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    >> Share

  105. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.
    >> Share

  106. NUNEZ I
    Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.
    >> Share

    February 2022
  107. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.
    >> Share


  108. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    >> Share

  109. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.
    >> Share

  110. PIECHOTTA V, Harder T
    Waning of COVID-19 vaccine effectiveness: individual and public health risk.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.
    >> Share

  111. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
    Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
    >> Share

  112. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    >> Share

  113. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
    Decoupling of omicron variant infections and severe COVID-19.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.
    >> Share

  114. EGGER S, Egger G
    The vaccinated propor-tion of people with COVID-19 needs context.
    Lancet. 2022;399:627.
    >> Share

  115. CAPLAN AL
    Stigma, vaccination, and moral accountability.
    Lancet. 2022;399:626-627.
    >> Share

  116. SAMARASEKERA U
    Ayoade Alakija: advancing equity in the COVID-19 response.
    Lancet. 2022;399:511.
    >> Share

  117. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.
    >> Share

  118. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

  119. NORDSTROM P, Ballin M, Nordstrom A
    Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
    Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
    >> Share

  120. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
    COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
    Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.
    >> Share


  121. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
    >> Share

    January 2022
  122. JAFFE S
    The next steps for US vaccine mandates.
    Lancet. 2022;399:425-426.
    >> Share


  123. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
    >> Share

  124. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
    Measles.
    Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
    >> Share

  125. FENDLER A, Shepherd STC, Au L, Wu M, et al
    Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
    Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.
    >> Share

  126. LANE R
    Jamal Rifi: family doctor building bridges in the community.
    Lancet. 2022;399:353.
    >> Share

  127. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
    Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
    >> Share

  128. BRAVO L, Smolenov I, Han HH, Li P, et al
    Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
    >> Share

  129. VESIKARI T
    Trimeric S protein COVID-19 vaccine needs to find its place.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.
    >> Share

  130. CARR EJ, Wu M, Harvey R, Billany RE, et al
    Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.
    >> Share

  131. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.
    >> Share

  132. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
    Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.
    >> Share

    December 2021
  133. KING J, Ferraz OLM, Jones A
    Mandatory COVID-19 vaccination and human rights.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.
    >> Share

  134. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
    >> Share

  135. KENNEDY RB
    Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.
    >> Share

  136. LEUNG K, Wu JT
    Managing waning vaccine protection against SARS-CoV-2 variants.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.
    >> Share

  137. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
    Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
    >> Share

  138. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
    Diagnostics for COVID-19: moving from pandemic response to control.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
    >> Share

  139. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
    COVID-19 vaccine strategies must focus on severe disease and global equity.
    Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.
    >> Share

  140. STUART ASV, Shaw RH, Liu X, Greenland M, et al
    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
    >> Share

  141. RICHARDSON CD
    Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.
    >> Share

  142. KARIM SSA, Karim QA
    Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.
    >> Share

  143. MENDELSON M, Venter F, Moshabela M, Gray G, et al
    The political theatre of the UK's travel ban on South Africa.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.
    >> Share

  144. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
    >> Share

    November 2021
  145. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.
    >> Share

  146. BURKI T
    mRNA discoveries earn the 2021 Prince Mahidol Award.
    Lancet. 2021;398:1865.
    >> Share

  147. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    >> Share

  148. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.
    >> Share

  149. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.
    >> Share

  150. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    >> Share

  151. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    >> Share

  152. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
    >> Share

  153. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.
    >> Share

  154. USHER AD
    New budget and strategy for ACT-A.
    Lancet. 2021;398:1677.
    >> Share

  155. ZAROCOSTAS J
    WHO's Tedros set to be re-elected unopposed.
    Lancet. 2021;398:1676.
    >> Share

  156. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
    >> Share

  157. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    >> Share

  158. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    >> Share

    October 2021
  159. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
    When suspicion replaces evidence in public health.
    Lancet. 2021;398:1565-1566.
    >> Share

  160. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    >> Share

  161. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
    >> Share

  162. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    >> Share

  163. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.
    >> Share

  164. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
    >> Share

  165. SAMARASEKERA U
    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.
    >> Share

  166. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.
    >> Share

  167. THE LANCET
    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.
    >> Share

  168. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
    >> Share

  169. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    >> Share

    September 2021
  170. THE LANCET
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.
    >> Share

  171. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share

  172. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    >> Share

  173. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    >> Share

    August 2021
  174. USHER AD
    Health leaders criticise limited ACT-A review.
    Lancet. 2021;398:650-651.
    >> Share

    July 2021
  175. KICKBUSCH I, Leung GM, Shattock RJ
    Learning from crisis: building resilient systems to combat future pandemics.
    Lancet. 2021;398:e2-e6.
    >> Share

    June 2021
  176. DANIELS JP
    Colombians protest over inequities and health care.
    Lancet. 2021;397:2454.
    >> Share

  177. USHER AD
    A beautiful idea: how COVAX has fallen short.
    Lancet. 2021;397:2322-2325.
    >> Share

  178. USHER AD
    ACT Accelerator strains donors' aid budgets.
    Lancet. 2021;397:2137.
    >> Share

    May 2021
  179. SAXENA SG, Godfrey T
    Catalysing needed change for health systems in the USA.
    Lancet. 2021;397:1705-1706.
    >> Share

  180. REINHART E, Dawes D, Maybank A
    Structural medicine: towards an economy of care.
    Lancet. 2021;397:1691-1693.
    >> Share

    March 2021
  181. THE LANCET
    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.
    >> Share

  182. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016